10January

Fiasp® (fast-acting insulin aspart) approved in Europe ... Read more

09January

Novo Nordisk and Glooko partner to develop digital health solutions for people w ... Read more

05December

Novo Nordisk files for regulatory approval of once-weekly semaglutide in the US ... Read more

03December

NovoSeven® resolved 96.5% of bleeds when initiated within one hour after bleed o ... Read more

16January

Novo Nordisk A/S - Share repurchase programme ... Read more

10January

Fiasp® (fast-acting insulin aspart) approved in Europe ... Read more

09January

Novo Nordisk A/S - Share repurchase programme ... Read more

02January

Novo Nordisk A/S - Status regarding Novo Nordisk's holding of its own shares (31 ... Read more

02February

Financial statement for the full year of 2016,

07February

PDF Version of Annual Report 2016 published,

23March

Annual General Meeting 2017,

01April

Silent period,

 

 

 

Investors

 
Share information


Take an advanced view of the Novo Nordisk share

 
FY 2016 financial results 


Access the Full Year 2016 conference call and material

 
Annual Report 2016
Annual Report


The Annual Report 2016 will be published on 7 February 2017



Novo Nordisk at a glance


Private shareholders


See relevant content for private investors



IR material


Download relevant Investor Relations material



Contacts



Subscriptions


Sign up to receive company announcements.



Annual Report 2015


Download the Novo Nordisk Annual Report 2015